Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds

Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds
A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess elsewhere) to ease motor problems in Parkinson’s disease. The FDA review was conducted after the findings ... read more
Source: Parkinson’s News TodayPublished on 2019-08-22By Jose Marques Lopes, PhD